Overview

Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805

Status:
Completed
Trial end date:
2011-10-03
Target enrollment:
Participant gender:
Summary
This is a single-center, randomized, two part, double-blind, crossover study in healthy adult subjects to assess the effect of a single dose of GSK2336805 150mg on cardiac function comparing with placebo using echocardiography as a primary assessment modality
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline